NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Donna Dea

Donna has more than two decades of regulatory experience in the pharmaceutical industry, with deep expertise in designing and implementing regulatory strategies for delivering new medicines to patients. Prior to operating a regulatory affairs consultancy, Donna spent 35 years with AstraZeneca, where she led the development and implementation of global regulatory strategies supporting the approval of new treatments for asthma, COPD, rhinitis, and atrial fibrillation, as well as for new device platforms, and was responsible for interactions with health authorities related to NDA/MAA submissions.